ABD - İngilizce - NLM (National Library of Medicine)

teva parenteral medicines, inc. - epoprostenol sodium (unii: 4k04iq1of4) (epoprostenol - unii:dcr9z582x0) - epoprostenol 0.5 mg - epoprostenol sodium for injection is indicated for the treatment of pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity. trials establishing effectiveness included predominantly (97%) patients with new york heart association (nyha) functional class iii-iv symptoms and etiologies of idiopathic or heritable pah (49%) or pah associated with connective tissue diseases (51%). epoprostenol is contraindicated in patients with heart failure caused by reduced left ventricular ejection fraction [see clinical studies ( 14.3)] . epoprostenol is contraindicated in patients with a hypersensitivity to the drug or any of its ingredients. risk summary limited published data from case series and case reports have not established an association with epoprostenol and major birth defects, miscarriage or adverse maternal or fetal outcomes when epoprostenol is used during pregnancy. there are risks to the mother and fetus from untreated pulmonary arterial hypertension (see clinical considerations) . in

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syntex s.a. - cloprostenol sodium - unknown - cloprostenol sodium prostaglandin active 0.0 - active constituent

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - cloprostenol sodium - unknown - cloprostenol sodium prostaglandin active 0.0 - active constituent

İsrail - İngilizce - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 1.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

İsrail - İngilizce - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 0.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

Malta - İngilizce - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.531 mg - antithrombotic agents

ABD - İngilizce - NLM (National Library of Medicine)

parnell technologies pty ltd - cloprostenol sodium (unii: 886sav9675) (cloprostenol - unii:4208238832) - cloprostenol 250 ug in 1 ml - approved by fda under anada # 200-310 estroplan (cloprostenol sodium) prostaglandin analogue for cattle equivalent to 250 mcg cloprostenol/ml caution: federal law restricts this drug to use by or on the order of a licensed veterinarian. description: estroplan (cloprostenol sodium) is a synthetic prostaglandin analogue structurally related to prostaglandin f2 α (pgf2 α ). each ml of the colorless aqueous solution contains 263 mcg of cloprostenol sodium (equivalent to 250 mcg of cloprostenol), chlorocresol 1.0 mg as a bactericide, citric acid anhydrous 0.66 mg, sodium citrate 5.03 mg, sodium chloride 6.76 mg. the ph is adjusted, as necessary, with sodium hydroxide or citric acid. action: estroplan causes functional and morphological regression of the corpus luteum (luteolysis) in cattle. in normal, nonpregnant cycling animals this effect on the life span of the corpus luteum usually results in estrus 2 to 5 days after treatment. in animals with prolonged luteal function (pyometra, mummified fetus, and

Kanada - İngilizce - Health Canada

modern veterinary therapeutics llc - cloprostenol (cloprostenol sodium) - solution - 175mcg - cloprostenol (cloprostenol sodium) 175mcg - swine (pigs)